Cartalax

Cartalax is the tripeptide Ala-Glu-Asp — three amino acids, about 333 daltons, one of roughly two dozen ultrashort peptides designed at the St Petersburg Institute of Bioregulation and Gerontology. The design method is worth stating plainly, because it explains the whole product line: the institute takes an extract of one animal tissue, runs mass spectrometry and HPLC on it, and resynthesises a short peptide it finds inside. AED is what came out of the cartilage extract, which is why it is sold as the synthetic sibling of Sigumir and marketed for joints.

What the cartilage-cell studies show

In human mesenchymal stem cells carried through repeated division until they age, AED at 200 ng/ml raised both gene expression and protein synthesis of the four canonical markers of chondrogenic differentiation: SOX9, aggrecan, type II collagen and COMP. The cartilage extract itself did the same at ten times the concentration, and did nothing to SOX9 or aggrecan at the lower one. AED's aggrecan effect runs the other way across its own two doses: present at 200 ng/ml, absent at 2,000.

The second study is in rat cells rather than human ones, and in chondrocytes grown out of intervertebral discs rather than a joint. Those cells showed the senescence-associated secretory phenotype — raised p16, p21, p53, TNF-alpha and IL-1-alpha and fallen Sirt1 — and AED lowered all three pro-apoptotic proteins and raised Sirt1. What it did not move was either cytokine. The cartilage extract is the one that lowered TNF-alpha and IL-1-alpha.

Those are the cells the product is named for, and the endpoints are the right ones. What they are not is tissue: no cartilage explant has been given AED and measured for matrix synthesis, and no animal has been given it and measured for cartilage. Rat cartilage explants from young and old animals do respond to synthetic bioregulatory tripeptides at concentrations as low as 0.05 ng/ml, with proliferation stimulated at both ages — but the three the paper tested are Lys-Glu-Asp, Glu-Asp-Arg and Glu-Asp-Gly, and Ala-Glu-Asp is not one of them. The explants are xiphoid-process cartilage rather than joint cartilage, and what was measured is the area of the growth zone.

The one animal study of the branded product is about bone. Old rats with a standardised cavity in the mandible, dosed for 30 days before surgery, formed at 60 to 120 days a regenerate with less connective and cartilaginous tissue and more advanced remodelling of new bone than controls or than rats dosed only from the day of surgery. Jaw-bone healing is a real endpoint; it is not a joint.

Where the evidence comes from

Twenty-eight records make up the appraised literature for Cartalax and Sigumir together. Three of them have no author from the St Petersburg institute: a 2025 review of the related tetrapeptide AEDG by pharmacy and geriatrics groups in Warsaw and Bydgoszcz, a 2025 telomere study of the same tetrapeptide from Brunel University London, and a study of short peptides in tobacco roots from the All-Russia Research Institute of Agricultural Biotechnology in Moscow. None of the three touches cartilage. The Western laboratory that has worked with these peptides — the University of Chieti-Pescara, which found AEDG and KED cutting senescence markers in oral stem cells — did so with the institute's founder as a co-author. The cartilage studies are institute-authored and published in Advances in Gerontology, the Russian-language journal the institute is tied to, and report no effect sizes in anything retrievable.

The independent review is the interesting one. Two Polish groups, no external funding, no declared conflict, read 25 years of work on this peptide series and concluded that the reported geroprotective and neuroendocrine effects are there in the record, that the mechanism remains unresolved, and that physico-chemical and structural work on the peptides is very limited.

The gene-regulation mechanism

The program's claim is that peptides this short act on DNA directly. Labelled short peptides of the series do enter the cytoplasm and the nucleus of cultured cells and bind specific oligonucleotide sequences in vitro, which is the experiment the claim rests on. Downstream, AED raises IGF1 expression several fold in aging stem cells, lowers MMP-9 and apoptosis in aging skin fibroblasts, and raises sirtuin-1, sirtuin-6 and type I collagen in the same fibroblast model. Type I collagen is the skin isoform — articular cartilage is built on type II, which is where the chondrogenic studies matter.

The related tetrapeptide AEDG carries the program's best-known claim, telomerase induction and telomere elongation in human somatic cells, published in 2003. A Brunel University group with no institute author reproduced the core of it in 2025, in two normal human cell lines over three weeks, and found that in two breast-cancer lines the same peptide lengthened telomeres by a different route instead. The one direct measurement of telomere length in donor lymphocytes found significant change in 7 of 11 people — longer in five, shorter in two, with the direction tracking whether the donor started below or above the group average.

Getting a tripeptide to a joint

This has been addressed once, and computationally. Docking 26 of the program's peptides against the amino-acid transporters LAT1 and LAT2 and the peptide transporters PEPT1 and PEPT2 put the whole set ahead of the 8,400 unselected di- and tripeptides at three of the four — a real finding about the series, with PEPT2 the exception the paper names, where thirteen of the twenty-six score unfavourably. AED itself ranked 14th of 26 at LAT1, 12th at LAT2, 13th at PEPT1 and 7th at PEPT2, and many of the unselected 8,400 score as well as or better than the series, which the paper reports and sets aside because nothing is known about their activity. Docking scores are computed binding estimates, not measured transport, and no plasma or tissue concentration of AED has been published for any species or route.

Regulatory status and safety

Cartalax has no FDA status of any kind. It is sold as a supplement, typically 10 to 20 mg capsules in 30-day courses and as a 2 ml injectable solution, with regeneration claims that no controlled human trial supports. A clinicaltrials.gov search in August 2026 found no registered trial of Cartalax, Sigumir or the related peptides.

No human safety data have been published, and the one study that dosed people — 104 men, two capsules twice daily for 60 days — reports nothing about tolerability or adverse events. Lifetime subcutaneous dosing of the related tetrapeptide AEDG in 108 mice left weight and food intake unchanged and lowered leukaemia incidence six-fold, which its authors read as evidence of safe long-term administration — a different peptide, species and route. A synthetic tripeptide built from three common amino acids is low-risk by inference. This entry is research appraisal, not dosing guidance.

What would move this to promising

A controlled human trial. One uncontrolled human study exists — 104 men with temporomandibular joint dysfunction took Cartalax for 60 days and their three-item severity score fell, with nobody untreated to compare them against. Any registered study of AED with a control arm and an endpoint someone outside the institute can check would change the tier faster than another culture experiment. Short of that, the two studies that would matter most are a cartilage-explant or joint-injury model with matrix-synthesis endpoints rather than marker expression, and a replication of the chondrocyte work by a laboratory with no institute author. The chondrogenic marker panel is a reasonable place for a peptide to start; the question the record leaves open is whether anything happens after the markers.